Stem cell therapy for the secretory system

The endocrine system is a “command center” composed of multiple organs responsible for producing and secreting hormones to regulate various bodily functions. These organs include the pituitary gland, thyroid, pancreas, adrenal glands, ovaries, and testes.

Common endocrine system diseases include diabetes, gout, obesity, osteoporosis, thyroid diseases, adrenal diseases, and hypothalamic diseases. However, the three most prevalent endocrine diseases globally are: diabetes, thyroid diseases, and osteoporosis.


I. Core Mechanisms: How Do Stem Cells Treat Endocrine Diseases?

Stem cells have emerged as a new star in treating endocrine diseases, relying primarily on the following three core mechanisms of action:

  • Cell Replacement and Repair
    Stem cells possess self-renewal and multi-directional differentiation capabilities, allowing them to differentiate into specific functional cell types, such as islet cells and thyroid cells. Through stem cell transplantation, damaged endocrine gland cells can be replaced, and the function of damaged tissues can be repaired.

  • Secretion of Bioactive Factors
    Stem cells can secrete a variety of bioactive factors (such as cytokines, growth factors, and hormones). These substances can regulate endocrine system functions, promote cell proliferation, differentiation, and repair, inhibit inflammatory responses, and modulate immune reactions.

  • Immunomodulation
    In many endocrine diseases, abnormal immune system activity drives disease progression. By regulating immune cell activity and secreting immune factors, stem cells can effectively inhibit inflammatory and autoimmune responses, thereby alleviating disease symptoms.


II. Clinical Practice: Stem Cells Can Treat Multiple Endocrine Diseases

1. Diabetes

Due to their unique properties, Mesenchymal Stem Cells (MSCs) are currently the most extensively studied stem cell type, showing broad regenerative medicine application prospects in treating diabetic patients.

A recent review published in the journal Diabetes, Metabolic Syndrome and Obesity detailed global clinical trials of MSCs for Type 2 Diabetes conducted over the decade from 2011 to 2021.

🔍 Key Study Data:

  • Reduced Medication: During the 12-month follow-up period, MSC treatment effectively reduced the dosage of anti-diabetic medications. Effective therapeutic doses ranged from 1×106 cells/kg to 3.7×106 cells/kg.

  • Significant Biomarker Improvement: Post-treatment, HbA1c (glycated hemoglobin) levels decreased by an average of 32%, and fasting blood glucose levels decreased by an average of 45%.

  • Islet Function Recovery: C-peptide levels decreased by an average of 38% in 2 trials and increased by 36% in 4 trials.

  • Safety: No severe adverse events were observed in any of the trials.

Conclusion: The analysis concluded that MSC therapy for Type 2 Diabetes is both safe and effective.


2. Hypothyroidism

Hypothyroidism is associated with bone metabolism disorders, and MSCs can secrete various factors that stimulate bone regeneration. A study in an American journal investigated the effect of MSC-conditioned medium (CM) on bone defects in hypothyroid rats.

 Research Methodology:
24 male rats were randomly divided into three groups:

  1. Hypothyroidism + Bone Defect (HYPO group)

  2. Hypothyroidism + Bone Defect + CM (HYPO+CM group)

  3. No Hypothyroidism + Bone Defect (Control group)
    (Note: Four weeks post-surgery, the right tibia was removed for biomechanical and histological examination.)

📊 Research Results:
Compared to the control group, bending stiffness, maximum load, and high-stress load were significantly reduced in the osteotomy sites of hypothyroid rats; trabecular bone volume (3.86±3.88) and the number of osteocytes (5800±859.8) were also significantly decreased (P < 0.01 and P < 0.02).

 Research Conclusion:
The application of MSC-conditioned medium (CM) can promote fracture regeneration and accelerate bone healing at the osteotomy site in hypothyroid rats.


3. Osteoporosis

A clinical study published in the Stem Cell Journal showed that perinatal tissue-derived MSCs help improve physical function in patients with osteoporotic vertebral compression fractures.

This was the first stem cell clinical trial for patients with osteoporotic vertebral compression fractures (a randomized, open-label Phase I/IIa study) involving 20 patients. The drugs involved were teriparatide (an osteoporosis drug that preferentially stimulates osteoblast activity) and umbilical cord MSCs.

 Study Design:

  • Group 1: Teriparatide alone

  • Group 2: Teriparatide combined with MSCs (Combination Group)
    (Note: Of the 20 patients, 14 completed the follow-up assessment, with 7 in each group.)

Leave a reply